Meeting Coverage

A large amount of preclinical and clinical research has been dedicated to remyelination in MS,...

A non-inferiority comparative study failed to demonstrate that treatment with rituximab is...

An analysis of patient-reported outcomes (PRO) over a 10-year period suggests that physical...

Non-disabling relapses (NDRs) that occur early in the course of relapsing-remitting MS (RRMS) are...

For the first time, a randomized, placebo-controlled trial demonstrated beneficial effects of a...

For a presentation at the 2022 European Committee for Treatment and Research in Multiple Sclerosis...

Data from a randomized controlled trial presented at the European Committee for Treatment and...

A prospective, longitudinal, multicenter study of 217 patients with neuromyelitis optica spectrum...

A new study suggests B-cell depleting anti-CD20 monoclonal antibodies (mAbs) such as ocrelizumab...

Anti-CD20 therapies do not fully resolve chronic, active/smoldering lesions, visible on MRI as...

For a variety of reasons, patients with relapsing-remitting MS (RRMS) together with their...

In patients with aged 10-17 and treated with fingolimod for up to 6 years in the PARADIGMS study,...

From observational, single-arm cohorts, autologous hematopoietic stem cell transplantation (AHSCT)...

At a prize-winning poster presented at the European Committee for Treatment and Research in...

A large study conducted in European nationwide data sources found no evidence that teriflunomide...